Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Vibrio cholerae accessory colonisation factor AcfC: a chemotactic protein with a role in hyperinfectivity.

Valiente E, Davies C, Mills DC, Getino M, Ritchie JM, Wren BW.

Sci Rep. 2018 May 30;8(1):8390. doi: 10.1038/s41598-018-26570-7.

2.

The Type B Flagellin of Hypervirulent Clostridium difficile Is Modified with Novel Sulfonated Peptidylamido-glycans.

Bouché L, Panico M, Hitchen P, Binet D, Sastre F, Faulds-Pain A, Valiente E, Vinogradov E, Aubry A, Fulton K, Twine S, Logan SM, Wren BW, Dell A, Morris HR.

J Biol Chem. 2016 Dec 2;291(49):25439-25449. Epub 2016 Oct 7.

3.

Role of Glycosyltransferases Modifying Type B Flagellin of Emerging Hypervirulent Clostridium difficile Lineages and Their Impact on Motility and Biofilm Formation.

Valiente E, Bouché L, Hitchen P, Faulds-Pain A, Songane M, Dawson LF, Donahue E, Stabler RA, Panico M, Morris HR, Bajaj-Elliott M, Logan SM, Dell A, Wren BW.

J Biol Chem. 2016 Dec 2;291(49):25450-25461. Epub 2016 Oct 4.

4.

Micro and Macroscale Drivers of Nutrient Concentrations in Urban Streams in South, Central and North America.

Loiselle SA, Gasparini Fernandes Cunha D, Shupe S, Valiente E, Rocha L, Heasley E, Belmont PP, Baruch A.

PLoS One. 2016 Sep 23;11(9):e0162684. doi: 10.1371/journal.pone.0162684. eCollection 2016.

5.

Nitrogen fixation in a non-heterocystous cyanobacterial mat from a mountain river.

Berrendero E, Valiente EF, Perona E, Gómez CL, Loza V, Muñoz-Martín MÁ, Mateo P.

Sci Rep. 2016 Aug 1;6:30920. doi: 10.1038/srep30920.

6.

Clostridium difficile has a single sortase, SrtB, that can be inhibited by small-molecule inhibitors.

Donahue EH, Dawson LF, Valiente E, Firth-Clark S, Major MR, Littler E, Perrior TR, Wren BW.

BMC Microbiol. 2014 Aug 31;14:219. doi: 10.1186/s12866-014-0219-1.

7.

The post-translational modification of the Clostridium difficile flagellin affects motility, cell surface properties and virulence.

Faulds-Pain A, Twine SM, Vinogradov E, Strong PC, Dell A, Buckley AM, Douce GR, Valiente E, Logan SM, Wren BW.

Mol Microbiol. 2014 Oct;94(2):272-89. doi: 10.1111/mmi.12755. Epub 2014 Sep 15.

8.

The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move.

Valiente E, Cairns MD, Wren BW.

Clin Microbiol Infect. 2014 May;20(5):396-404. doi: 10.1111/1469-0691.12619. Epub 2014 Apr 28. Review.

9.

Detection of new SHV-12, SHV-5 and SHV-2a variants of extended spectrum beta-lactamase in Klebsiella pneumoniae in Egypt.

Newire EA, Ahmed SF, House B, Valiente E, Pimentel G.

Ann Clin Microbiol Antimicrob. 2013 Jul 18;12:16. doi: 10.1186/1476-0711-12-16.

10.

Quality of life in hearing-impaired children with bilateral hearing devices.

Pérez-Mora R, Lassaletta L, Castro A, Herrán B, San-Román-Montero J, Valiente E, Gavilán J.

B-ENT. 2012;8(4):251-5.

PMID:
23409552
11.

Characterisation of Clostridium difficile biofilm formation, a role for Spo0A.

Dawson LF, Valiente E, Faulds-Pain A, Donahue EH, Wren BW.

PLoS One. 2012;7(12):e50527. doi: 10.1371/journal.pone.0050527. Epub 2012 Dec 7.

12.

Macro and micro diversity of Clostridium difficile isolates from diverse sources and geographical locations.

Stabler RA, Dawson LF, Valiente E, Cairns MD, Martin MJ, Donahue EH, Riley TV, Songer JG, Kuijper EJ, Dingle KE, Wren BW.

PLoS One. 2012;7(3):e31559. doi: 10.1371/journal.pone.0031559. Epub 2012 Mar 2.

13.

Hypervirulent Clostridium difficile PCR-ribotypes exhibit resistance to widely used disinfectants.

Dawson LF, Valiente E, Donahue EH, Birchenough G, Wren BW.

PLoS One. 2011;6(10):e25754. doi: 10.1371/journal.pone.0025754. Epub 2011 Oct 25.

14.

Emergence of new PCR ribotypes from the hypervirulent Clostridium difficile 027 lineage.

Valiente E, Dawson LF, Cairns MD, Stabler RA, Wren BW.

J Med Microbiol. 2012 Jan;61(Pt 1):49-56. doi: 10.1099/jmm.0.036194-0. Epub 2011 Sep 8.

15.

In-depth genetic analysis of Clostridium difficile PCR-ribotype 027 strains reveals high genome fluidity including point mutations and inversions.

Stabler RA, Valiente E, Dawson LF, He M, Parkhill J, Wren BW.

Gut Microbes. 2010 Jul;1(4):269-276. Epub 2010 Mar 16.

16.

Glycoproteomics: a powerful tool for characterizing the diverse glycoforms of bacterial pilins and flagellins.

Hitchen PG, Twigger K, Valiente E, Langdon RH, Wren BW, Dell A.

Biochem Soc Trans. 2010 Oct;38(5):1307-13. doi: 10.1042/BST0381307. Review.

PMID:
20863304
17.

A comparative epizootiologic study of the two fish-pathogenic serovars of Vibrio vulnificus biotype 2.

Fouz B, Llorens A, Valiente E, Amaro C.

J Fish Dis. 2010 May;33(5):383-90. doi: 10.1111/j.1365-2761.2009.01130.x. Epub 2010 Feb 12.

PMID:
20158583
18.

Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium.

Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW.

Genome Biol. 2009;10(9):R102. doi: 10.1186/gb-2009-10-9-r102. Epub 2009 Sep 25.

19.

Clostridium difficile--a continually evolving and problematic pathogen.

Dawson LF, Valiente E, Wren BW.

Infect Genet Evol. 2009 Dec;9(6):1410-7. doi: 10.1016/j.meegid.2009.06.005. Epub 2009 Jun 16.

PMID:
19539054
20.

Vibrio vulnificus produces quorum sensing signals of the AHL-class.

Valiente E, Bruhn JB, Nielsen KF, Larsen JL, Roig FJ, Gram L, Amaro C.

FEMS Microbiol Ecol. 2009 Jul;69(1):16-26. doi: 10.1111/j.1574-6941.2009.00691.x. Epub 2009 Apr 25.

21.

Microbial and histopathological study of the vibriosis caused by Vibrio vulnificus serovar E in eels: the metalloprotease Vvp is not an essential lesional factor.

Valiente E, Padrós F, Lamas J, Llorens A, Amaro C.

Microb Pathog. 2008 Nov-Dec;45(5-6):386-93. doi: 10.1016/j.micpath.2008.09.001. Epub 2008 Sep 27.

PMID:
18930131
22.

Vibrio vulnificus biotype 2 serovar E gne but not galE is essential for lipopolysaccharide biosynthesis and virulence.

Valiente E, Jiménez N, Merino S, Tomás JM, Amaro C.

Infect Immun. 2008 Apr;76(4):1628-38. doi: 10.1128/IAI.01393-07. Epub 2008 Jan 28.

23.

A common virulence plasmid in biotype 2 Vibrio vulnificus and its dissemination aided by a conjugal plasmid.

Lee CT, Amaro C, Wu KM, Valiente E, Chang YF, Tsai SF, Chang CH, Hor LI.

J Bacteriol. 2008 Mar;190(5):1638-48. Epub 2007 Dec 21.

24.

Role of the virulence plasmid pR99 and the metalloprotease Vvp in resistance of Vibrio vulnificus serovar E to eel innate immunity.

Valiente E, Lee CT, Lamas J, Hor L, Amaro C.

Fish Shellfish Immunol. 2008 Jan;24(1):134-41. Epub 2007 Oct 25.

PMID:
18053741
25.

Role of the metalloprotease Vvp and the virulence plasmid pR99 of Vibrio vulnificus serovar E in surface colonization and fish virulence.

Valiente E, Lee CT, Hor LI, Fouz B, Amaro C.

Environ Microbiol. 2008 Feb;10(2):328-38. Epub 2007 Nov 19.

PMID:
18028416
26.

[Stressful life events as risk factors in acute cerebrovascular disease].

Peris A, Martín-González R, Valiente E, Ruiz A, Vioque J.

Rev Neurol. 1997 Dec;25(148):1871-5. Spanish.

PMID:
9528020
27.

[Quality and life style as risk factors in acute cerebrovascular disease].

Peris A, Martín-González R, Valiente E, Ruiz A, Vioque J.

Rev Neurol. 1997 Dec;25(148):1866-71. Spanish.

PMID:
9528019
28.

[Cerebral blood flow study using SPECT in patients with memory disorders].

Valiente E, Botella MS, Martín R, Serrano J, Verdú J, Caballero O.

Rev Neurol. 1997 Mar;25(139):460-4. Spanish.

PMID:
9147787
29.
30.

[Validation of Allen's scale for the diagnosis of stroke].

Valiente E, Martín R, Gracia F, Muñiz R, Asensio M, Matías-Guiu J.

Rev Neurol. 1996 Jun;24(130):638-42. Spanish.

PMID:
8653606
31.

Arteriovenous fistulae complicating central venous catheterization: value of endovascular treatment based on a series of seven cases.

Ricolfi F, Valiente E, Bodson F, Poquet E, Chiras J, Gaston A.

Intensive Care Med. 1995 Dec;21(12):1043-7.

PMID:
8750133
32.

[The assessment of neurological care needs in the health sector of de San Juan de Alicante by key-informants model].

Martín R, Puigserver MT, Delgado JM, Valiente E, Matías-Guiu J.

Rev Neurol. 1995 Jul-Aug;23(122):860-5. Spanish.

PMID:
7497252
33.

[Percutaneous vertebral biopsy].

Brugières P, Ricolfi F, Valiente E, Thomas P, Qanadli S, Gaston A.

Rev Prat. 1994 Jun 15;44(12):1595-9. French.

PMID:
7939234
34.

Concentric MR patterns in multiple sclerosis. Report of two cases.

Revel MP, Valiente E, Gray F, Beges C, Degos JD, Brugières P, Gaston A.

J Neuroradiol. 1993 Dec;20(4):252-7. English, French.

PMID:
8308543
35.

Contribution of computerized tomography to the diagnosis of acute cerebral ischaemia.

Gaston A, Thomas P, Valiente E, Chakir N, Combes C.

J Neuroradiol. 1993 Jun;20(2):121-38. Review. English, French. No abstract available.

PMID:
8360723
36.

[Spontaneous complete rupture of the thoracic aorta. Apropos of a case surgically treated with success].

Abassade P, Baudouy PY, Laborde F, Gerardin B, Valiente E, Longueville G, Valleteau de Moulliac M.

Ann Cardiol Angeiol (Paris). 1992 Apr;41(4):215-8. French.

PMID:
1642439
37.

Supraperiosteal lifting of the upper two-thirds of the face.

De La Plaza R, Valiente E, Arroyo JM.

Br J Plast Surg. 1991 Jul;44(5):325-32. Erratum in: Br J Plast Surg 1992 Feb-Mar;45(2):185. Br J Plast Surg 1992 Jan;45(1):80.

PMID:
1873609
38.

[Surgical treatment of eyelid tumors].

Serra JM, Valiente E, Paloma V, Samayoa V, Ordiales G, Mesa F.

Rev Med Univ Navarra. 1989 Jan-Mar;33(1):41-9. Review. Spanish.

PMID:
2490181
39.

Neurotization of the remaining latissimus dorsi muscle following muscle flap transplant.

Serra JM, Samayoa V, Valiente E, Kloehn G.

J Reconstr Microsurg. 1988 Oct;4(5):415-20.

PMID:
3199354
40.

[Acquired eyelid ptosis. Treatment protocol].

Serra JM, Marqués de Moura A, Samayoa V, Valiente E, Paloma V.

Rev Med Univ Navarra. 1988 Oct-Dec;32(4):223-7. Spanish. No abstract available.

PMID:
3154967
41.

Supplemental Content

Loading ...
Support Center